Congress Reports

The American Heart Association (AHA) meeting takes place in Dallas, USA, November 13th-16th, 2005. InCirculation.net aims to keep you up-to-date with the latest developments with exclusive reports from key selected sessions, including satellite symposia, mini-courses, poster presentations, and oral contributions.

Highlights from the 41st Annual Meeting of the European Association for the Study of Diabetes, Athens, Greece, 10-15 September. Here you will find news and exclusive reports from key selected sessions.

The European Society of Cardiology meeting takes place 3 -7 September 2005 in Stockholm, Sweden. Read our reports and news from the congress as they come in.

A selection of congress reports and news articles from the International Society of Thrombosis and Haemostasis meeting, 6-12 August in Sydney, Australia, are now available.

We have reported from Heart Failure 2005 held in Lisbon, Portugal 11 -14 June. A selection of reports are available.

The 65th annual sessions of the American Diabetes Association held in San Diego, USA 10 - 14 June have now been reported. A selection of reports are available here.

Read a selection of reports from the 2005 American Society of Hypertension Meeting (ASH-HYP) held in San Francisco, CA held between the 14 - 19 May.

InCirculation.net reported from the European Atherosclerosis Society meeting 2005 in Prague. Reports published throughout the congress, which ran from the 23 April until April 27, are available to read.

InCirculation.net reported from the American College of Cardiology Annual Scientific Sessions 2005. Reports published throughout the congress, which ran from March 5 until March 9, can be read here.For more information on the meeting, visit the Congress calendar.

Evolving role of angiotensin receptor blockade in cardiovascular diseaseAt this AstraZeneca-sponsored symposium, held 26–27 February 2005 in Lisbon, Portugal, delegates discussed the pivotal role of the angiotensin type 1 (AT1)-receptor in the cardiovascular disease (CVD) continuum, and the growing body of evidence supporting AT1-receptor antagonism as a strategy to prevent CVD progression. The two-day meeting featured lectures and discussions given by a distinguished panel o